Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development

Published:2017-01-12 Issue:2 Volume:19 Page:377-385
ISSN:1550-7416
Container-title:The AAPS Journal
language:en
Short-container-title:AAPS J

Author:

Salazar-Fontana Laura I.,Desai Dharmesh D.,Khan Tarik A.,Pillutla Renuka C.,Prior Sandra,Ramakrishnan Radha,Schneider Jennifer,Joseph Alexandra

Publisher

Springer Science and Business Media LLC

Subject

Pharmaceutical Science

Link

http://link.springer.com/content/pdf/10.1208/s12248-016-0030-z.pdf

Reference101 articles.

1. Malucchi S, Bertolotto A. Clinical aspects of immunogenicity to biopharmaceuticals. In: Weert M, Moller EH, editors. Immunogenicity of biopharmaceuticals. Biotechnology: pharmaceutical aspects. XII. 1st ed. New York: Springer; 2008. p. 27–56.

2. Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305(14):1460–8.

3. Goodnow CC. Transgenic mice and analysis of B-cell tolerance. Annu Rev Immunol. 1992;10:489–518.

4. Hogquist KA, Baldwin TA, Jameson SC. Central tolerance: learning self-control in the thymus. Nat Rev Immunol. 2005;5(10):772–82.

5. Khan TA, Reddy ST. Immunological principles regulating immunomodulation with biomaterials. Acta Biomater. 2014;10(4):1720–7.

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Submicron immunoglobulin particles exhibit FcγRII-dependent toxicity linked to autophagy in TNFα-stimulated endothelial cells;Cellular and Molecular Life Sciences;2024-08-30

2. The European Bioanalysis Forum recommendation on establishing appropriate drug tolerance levels in antidrug antibody assays;Bioanalysis;2024-08-05

3. Therapeutic proteins: developments, progress, challenges, and future perspectives;3 Biotech;2024-03-18

4. Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors;Clinical Cancer Research;2024-02-06

5. Immunogenicity and Immune-Related Adverse Drug Reactions;Reference Module in Biomedical Sciences;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3